New hope for men with Hard-to-Treat prostate cancer?

NCT ID NCT06067841

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called BMS-986460 in 140 men with metastatic castration-resistant prostate cancer, a type that no longer responds to standard hormone therapy. The main goals are to check the drug's safety and find the right dose, while also looking for signs that it might shrink tumors or lower PSA levels. Participants must have already tried at least one other hormone treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986460
What this could lead to: If successful, this could lead to a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early Phase 1 trial with only 140 participants, focused on safety. The drug may not prove effective or could have significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma neoplasm prostate cancer Prostatic Neoplasms, Castration-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Phone: •••-•••-••••
Duke Cancer Institute
RECRUITING

Durham, North Carolina, 27710, United States

Contact Phone: •••-•••-••••
Florida Cancer Specialists Sarasota Drug Development Unit
RECRUITING

Sarasota, Florida, 34232, United States

Contact Phone: •••-•••-••••
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-••••
Local Institution - 0006
WITHDRAWN

San Antonio, Texas, 78229, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact Phone: •••-•••-••••
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States

Contact Phone: •••-•••-••••
Stanford Cancer Center
RECRUITING

Palo Alto, California, 94304, United States

Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.